tetanus toxoid
Vaccineapproved
Approved
May 25, 1934
Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence. — Wikipedia
Clinical trial activity
75 trials · 64 clinical orgs · 2 marketing orgs
Phase 1
22
Phase 2
43
Phase 3
23
Phase 4
11
Earliest trial started Oct 1, 1999 (NCT00001119)
Timeline
1920s
- Jun 1, 1924
Evidence of US Marketing
1930s
- May 25, 1934
Earliest FDA Approval
1990s
- Dec 9, 1999
Sanofi-Aventis — First NDA Organization
- Dec 9, 1999
Sanofi-Aventis — NDA Secondary Org
- Dec 9, 1999
Sanofi-Aventis — NDA Organization
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2005
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
- Jun 24, 2008
GlaxoSmithKline — NDA Secondary Org
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Arthritis, Rheumatoid · Phase 4
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Clostridium Infections · Phase 2
- Colorectal Neoplasms · Phase 2
- Conjunctival Neoplasms · Phase 1
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 3
- Diphtheria Toxoid · Phase 2
- Ependymoma · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Haemophilus influenzae type b · Phase 3
- Hamartoma · Phase 2
- Healthy Volunteers · Phase 3
- Hepatitis B · Phase 3
- HIV Infections · Phase 2
- Kidney Transplantation · Phase 4
- Leukemia · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Malaria, Falciparum · Phase 3
- Medulloblastoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Meningitis · Phase 3
- Meningitis, Meningococcal · Phase 4
- Meningococcal Infections · Phase 4
- Multiple Myeloma · Phase 2
- Multiple Sclerosis · Phase 4
- Neoplasms · Phase 1/Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Only Child · Phase 3
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pertussis Vaccine · Phase 3
- Pneumococcal Infections · Phase 4
- Pneumonia · Phase 3
- Poliomyelitis · Phase 3
- Snake Bites · Phase 4
- Tetanus · Phase 4
- Vaccines · Phase 4
- Whooping Cough · Phase 4
Mechanism of action
- Tetanus toxoidVACCINE ANTIGEN
Tetanus toxoid vaccine antigen
- Clostridium tetaniImmunity, active
Clostridium tetani immunity, active
Approval history
- approvedMay 25, 1934
- approvedJun 1, 1924
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTetanus vaccine ↗
- NCATSK3W1N8YP13 ↗
- ChEMBLCHEMBL2108876 ↗
- ChEMBLCHEMBL2108875 ↗
Also known as
- clostridium tetani toxoid antigen (formaldehyde inactivated)
- tetanus
- tetanus
- tetanus antitoxin (equine)
- tetanus peptide
- tetanus toxin
- tetanus toxoid
- tetanus toxoid
- tetanus toxoid
- tetanus toxoid
- tetanus toxoid adsorbed
- tetanus toxoid adsorbed
- tetanus toxoid, adsorbed
- tetanus toxoid vaccine
- tetanus toxoid vaccine, inactivated
- tetanus vaccine
- the tizzoni preparation (equine)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06939777 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | China National Pharmaceutical Group |
| NCT06639607 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | National Cancer Institute (NCI), Washington University in St. Louis |
| NCT06639074 | Phase 2 | Nov 12, 2024 | Mayo Clinic |
| NCT06903221 | Phase 4 | Oct 16, 2024 | Radboud University |
| NCT06360250 | Early Phase 1 (Phase 1) | Apr 10, 2024 | Anning City First People's Hospital, Changchun BCHT Biotechnology Co., Yunnan University of Traditional Chinese Medicine |
| NCT06228586 | Phase 3 | Jan 18, 2024 | Sanofi-Aventis |
| NCT06123663 | Phase 1 | Dec 31, 2023 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06120751 | Phase 3 | Dec 31, 2023 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT06056050 | Phase 1 | Dec 6, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT06049940 | Phase 3 | Sep 1, 2023 | China National Pharmaceutical Group, Government of China |
| NCT05870618 | Phase 4 | May 31, 2023 | China National Biotec Group Co., Ltd, Government of China |
| NCT05870631 | Phase 4 | May 31, 2023 | China National Biotec Group Co., Ltd, Government of China |
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
| NCT06302374 | Phase 1/Phase 2 (Phase 2) | Mar 4, 2023 | Government of China |
| NCT05480462 | Phase 3 | Aug 31, 2022 | IBSS Biomed S.A. |
| NCT06607380 | Phase 1 | Aug 13, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Peking University |
| NCT05093829 | Phase 3 | Feb 28, 2022 | Emory University, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland |
| NCT04936685 | Phase 3 | Feb 21, 2022 | Sanofi, Sanofi-Aventis |
| NCT04319380 | Phase 3 | May 31, 2020 | Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO), Institut et Haute école de la Santé, La Source, Malaria Research and Training Center, Bamako, Mali, University of London |
| NCT03890367 | Phase 3 | Jul 19, 2019 | Sanofi-Aventis |
Showing 20 of 75 trials
Page 1 / 4
Organizations
Research & Development (64)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi-Aventis | For profit | 10 | 9 | 2 | 2009 |
| National Cancer Institute (NCI) | Government | 9 | 0 | 2 | 2001 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 7 | 6 | 4 | 1999 |
| Sanofi | For profit | 7 | 6 | 2 | 2014 |
| University of Virginia | Academic/Hospital | 7 | 7 | 2 | 2004 |
| Duke University | Academic/Hospital | 6 | 6 | 2 | 2006 |
| Government of China | Government | 6 | 3 | 4 | 2023 |
| National Institutes of Health (NIH) | Government | 4 | 0 | 2 | 2000 |
| Tianjin Cansino Biotechnology Inc | For profit | 3 | 3 | 2 | 2023 |
| Bristol-Myers Squibb | For profit | 2 | 2 | 2 | 2004 |
| China National Biotec Group Co., Ltd | For profit | 2 | 0 | 1 | 2023 |
| China National Pharmaceutical Group | For profit | 2 | 2 | 2 | 2023 |
| Emory University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Genentech | For profit | 2 | 2 | 2 | 2006 |
| GlaxoSmithKline | For profit | 2 | 2 | 1 | 2005 |
| Novartis | For profit | 2 | 2 | 2 | 2010 |
| Radboud University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| University of London | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Annias Immunotherapeutics, Inc. | For profit | 1 | 0 | 1 | 2016 |
| Anning City First People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
64 organizations
Page 1 / 4
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA2 | Jun 24, 2008 |
| Sanofi-Aventis | For profit | NDA2 | Dec 9, 1999 |
| Sanofi-Aventis | For profit | NDA | Dec 9, 1999 |